

# **Curriculum Vitae**

## **Prof. Dr. Iris Löw-Friedrich**

### **Personal data**

Year of birth: 1960

Nationality: German

Independence: +

### **Member and Chair of the Supervisory Board of Evotec**

First appointment: 2014

Current term of office: General Annual Meeting 2024 – 2026

Chair: Since 6/2021

2019 – 2021 Vice-Chair of the Supervisory Board

Committees: Remuneration Committee (Chair)

Previously: Member of the Audit and Compliance Committee

### **Competences and experiences**

Profound and extensive experience in the worldwide Development of medicines, small molecules and biologics, in different disease areas, including immunological, neurological and bone diseases, through executive leadership positions in the biopharmaceutical industry for more than 20 years, resulting in launches of more than 10 new molecular entities. Passionate about digitalization resulting in the early implementation of heavily digitalized and data-enabled processes across the entire clinical development continuum. A long-standing career as Chief Medical Officer with deep experience in benefit risk stewardship and oversight for the entire product portfolio and pipeline, including the representation of the pipeline strategy and execution to the capital markets. As a member of Management Boards, uninterrupted from 2001 to 2024, possesses in-depth knowledge and experience in general management, M&A, technology- and data-enabled innovation, risk management, financial performance reporting, accounting and sustainability.

Experience as a member of various Boards in the life sciences industry, covering the entire range from small biotechnology to large-scale healthcare companies (Evotec SE, Fresenius SE, SOBI, Celosia), ensuring strategy development and oversight of operational execution, state-of-the-art compensation and risk management systems.

## Career highlights

|             |   |
|-------------|---|
| 2008 – 2024 | UCB SA<br>Chief Medical Officer and Executive Vice President Development; member of the Executive Committee   |
| 2001 – 2007 | Schwarz Pharma AG<br>Global Head of Research and Development; member of the Management Board (since 2007 with UCB following the acquisition of Schwarz Pharma AG) |
| 2000 – 2001 | BASF Pharma<br>Vice President Global Projects   |
| 1992 – 2000 | Hoechst AG (and via M&A: Hoechst Marion Roussel, Aventis)<br>Various positions in Clinical Development, most recent position: Vice President Clinical Development |

## Qualifications

Goethe University Frankfurt am Main, Faculty of Medicine

- Since 2000: Clinical Professor for Internal Medicine (visiting)
- 1992: Venia legendi (*Habilitation*)
- 1985: Promotion (*Dr. med.*)
- 1979 – 1985: Study of Medicine

## Current mandates in listed companies

Evotec SE, Hamburg/Germany  
*(listed on the Frankfurt Stock Exchange and NASDAQ, New York)*

Chair of the Supervisory Board

Fresenius SE & Co. KGaA, Bad Homburg/Germany  
*(listed on the Frankfurt, Düsseldorf and München Stock Exchange)*

Member of the Supervisory Board

Swedish Orphan Biovitrum AB (SOBI),  
 Stockholm/Sweden  
*(listed on the Stockholm Stock Exchange)*

Member of the Supervisory Board

Financière de Tubize SA, Brussels, Belgium  
*(listed on Euronext, Brussels)*

Member of the Board

## Current mandates in non-listed companies

Celosia Therapeutics Pty Ltd.,  
 New South Wales/Australia

Member of the Company (Supervisory) Board